Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) – Research analysts at Cantor Fitzgerald raised their FY2022 EPS estimates for Spero Therapeutics in a report issued on Thursday, August 11th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of ($2.42) per share for the year, up from their previous estimate of ($3.34). The consensus estimate for Spero Therapeutics’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for Spero Therapeutics’ FY2023 earnings at ($1.27) EPS.
Spero Therapeutics (NASDAQ:SPRO – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to the consensus estimate of $2.85 million. Spero Therapeutics had a negative return on equity of 151.75% and a negative net margin of 1,147.64%. During the same period in the prior year, the firm earned ($0.66) earnings per share.
Spero Therapeutics Stock Down 0.8 %
Spero Therapeutics stock opened at $0.90 on Monday. The company has a market capitalization of $31.43 million, a PE ratio of -0.26 and a beta of 1.95. The firm has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $4.40. Spero Therapeutics has a twelve month low of $0.68 and a twelve month high of $19.87.
Hedge Funds Weigh In On Spero Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Kingsbury Capital Investment Advisors LLC purchased a new position in shares of Spero Therapeutics during the second quarter valued at about $45,000. Engineers Gate Manager LP purchased a new position in shares of Spero Therapeutics during the first quarter valued at about $95,000. Assenagon Asset Management S.A. increased its position in shares of Spero Therapeutics by 466.6% during the second quarter. Assenagon Asset Management S.A. now owns 131,020 shares of the company’s stock valued at $97,000 after buying an additional 107,897 shares during the period. XTX Topco Ltd purchased a new position in shares of Spero Therapeutics during the first quarter valued at about $115,000. Finally, AQR Capital Management LLC purchased a new position in shares of Spero Therapeutics during the second quarter valued at about $115,000. 69.36% of the stock is owned by institutional investors.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
- Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Why Apple is Primed to Take a Bite Out of Live Sports
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.